Jessica Moe1,2,3, Jesse Godwin1,2, Roy Purssell1,2,3, Fiona O'Sullivan1, Jeffrey P Hau1, Elizabeth Purssell1, Jason Curran4, Mary M Doyle-Waters5, Penelope M A Brasher5, Jane A Buxton3,6, Corinne M Hohl1,2,5. 1. Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada. 2. Department of Emergency Medicine, Vancouver General Hospital, Vancouver, BC, Canada. 3. British Columbia Centre for Disease Control, Vancouver, BC, Canada. 4. British Columbia Interior Health Authority, Kelowna, BC, Canada. 5. Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada. 6. School of Population and Public Health, University of British Columbia, Vancouver, BC.
Abstract
OBJECTIVES: Evaluate the relationship between naloxone dose (initial and cumulative) and opioid toxicity reversal and adverse events in undifferentiated and presumed fentanyl/ultra-potent opioid overdoses. METHODS: We searched Embase, MEDLINE, Cochrane Central Register of Controlled Trials, DARE, CINAHL, Science Citation Index, reference lists, toxicology websites, and conference proceedings (1972 to 2018). We included interventional, observational, and case studies/series reporting on naloxone dose and opioid toxicity reversal or adverse events in people >12 years old. RESULTS: A total of 174 studies (110 case reports/series, 57 observational, 7 interventional) with 26,660 subjects (median age 35 years; 74% male). Heterogeneity precluded meta-analysis. Where reported, we abstracted naloxone dose and proportion of patients with toxicity reversal. Among patients with presumed exposure to fentanyl/ultra-potent opioids, 56.9% (617/1,085) responded to an initial naloxone dose ≤0.4 mg compared with 80.2% (170/212) of heroin users, and 30.4% (7/23) responded to an initial naloxone dose >0.4 mg compared with 59.1% (1,434/2,428) of heroin users. Among patients who responded, median cumulative naloxone doses were higher for presumed fentanyl/ultra-potent opioids than heroin overdoses in North America, both before 2015 (fentanyl/ultra-potent opioids: 1.8 mg [interquartile interval {IQI}, 1.0, 4.0]; heroin: 0.8 mg [IQI, 0.4, 0.8]) and after 2015 (fentanyl/ultra-potent opioids: 3.4 mg [IQI, 3.0, 4.1]); heroin: 2 mg [IQI, 1.4, 2.0]). Where adverse events were reported, 11% (490/4,414) of subjects experienced withdrawal. Variable reporting, heterogeneity and poor-quality studies limit conclusions. CONCLUSIONS: Practitioners have used higher initial doses, and in some cases higher cumulative naloxone doses to reverse toxicity due to presumed fentanyl/ultra-potent opioid exposure compared with other opioids. High-quality comparative naloxone dosing studies assessing effectiveness and safety are needed.
OBJECTIVES: Evaluate the relationship between naloxone dose (initial and cumulative) and opioid toxicity reversal and adverse events in undifferentiated and presumed fentanyl/ultra-potent opioid overdoses. METHODS: We searched Embase, MEDLINE, Cochrane Central Register of Controlled Trials, DARE, CINAHL, Science Citation Index, reference lists, toxicology websites, and conference proceedings (1972 to 2018). We included interventional, observational, and case studies/series reporting on naloxone dose and opioid toxicity reversal or adverse events in people >12 years old. RESULTS: A total of 174 studies (110 case reports/series, 57 observational, 7 interventional) with 26,660 subjects (median age 35 years; 74% male). Heterogeneity precluded meta-analysis. Where reported, we abstracted naloxone dose and proportion of patients with toxicity reversal. Among patients with presumed exposure to fentanyl/ultra-potent opioids, 56.9% (617/1,085) responded to an initial naloxone dose ≤0.4 mg compared with 80.2% (170/212) of heroin users, and 30.4% (7/23) responded to an initial naloxone dose >0.4 mg compared with 59.1% (1,434/2,428) of heroin users. Among patients who responded, median cumulative naloxone doses were higher for presumed fentanyl/ultra-potent opioids than heroin overdoses in North America, both before 2015 (fentanyl/ultra-potent opioids: 1.8 mg [interquartile interval {IQI}, 1.0, 4.0]; heroin: 0.8 mg [IQI, 0.4, 0.8]) and after 2015 (fentanyl/ultra-potent opioids: 3.4 mg [IQI, 3.0, 4.1]); heroin: 2 mg [IQI, 1.4, 2.0]). Where adverse events were reported, 11% (490/4,414) of subjects experienced withdrawal. Variable reporting, heterogeneity and poor-quality studies limit conclusions. CONCLUSIONS: Practitioners have used higher initial doses, and in some cases higher cumulative naloxone doses to reverse toxicity due to presumed fentanyl/ultra-potent opioid exposure compared with other opioids. High-quality comparative naloxone dosing studies assessing effectiveness and safety are needed.
Entities:
Keywords:
Toxicology; public health; substance misuse
Authors: Stephen Parkin; Joanne Neale; Caral Brown; Aimee N C Campbell; Felipe Castillo; Jermaine D Jones; John Strang; Sandra D Comer Journal: Int J Drug Policy Date: 2020-04-15
Authors: Adrianna Rowe; Andrew Chang; Emily Lostchuck; Kathleen Lin; Frank Scheuermeyer; Victoria McCann; Jane Buxton; Jessica Moe; Raymond Cho; Paul Clerc; Connor McSweeney; Andy Jiang; Roy Purssell Journal: CJEM Date: 2022-06-07 Impact factor: 2.929
Authors: Joanne Neale; Nicola J Kalk; Stephen Parkin; Caral Brown; Laura Brandt; Aimee N C Campbell; Felipe Castillo; Jermaine D Jones; John Strang; Sandra D Comer Journal: J Subst Abuse Treat Date: 2020-08-05
Authors: Chelsea L Shover; Titilola O Falasinnu; Candice L Dwyer; Nayelie Benitez Santos; Nicole J Cunningham; Rohan B Freedman; Noel A Vest; Keith Humphreys Journal: Drug Alcohol Depend Date: 2020-09-28 Impact factor: 4.492
Authors: Amina Moustaqim-Barrette; Kristi Papamihali; Sierra Williams; Max Ferguson; Jessica Moe; Roy Purssell; Jane A Buxton Journal: PLoS One Date: 2021-10-29 Impact factor: 3.240
Authors: R Michael Krausz; Jean N Westenberg; Nickie Mathew; George Budd; James S H Wong; Vivian W L Tsang; Marc Vogel; Conor King; Vijay Seethapathy; Kerry Jang; Fiona Choi Journal: Int J Ment Health Syst Date: 2021-12-20
Authors: Stephen Parkin; Joanne Neale; Caral Brown; Jermaine D Jones; Laura Brandt; Felipe Castillo; Aimee N C Campbell; John Strang; Sandra D Comer Journal: Int J Drug Policy Date: 2020-10-20